NCT06575296 - Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 6, 2024

Primary Completion Date

April 29, 2028

Study Completion Date

April 29, 2028

Conditions

Acute LeukemiaAcute Leukemia of Ambiguous LineageAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChildhood Acute LeukemiaChildhood Acute Leukemia of Ambiguous LineageChildhood Acute Lymphoblastic LeukemiaChildhood Acute Myeloid Leukemia

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Echocardiography

Undergo ECHO

OTHER

Electronic Health Record Review

Ancillary studies

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Revumenib

Given PO

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER